Detailed answers about DANOS PHARMA INTERNATIONAL LTD, including incorporation, status, business activity, and accounts information.
When was DANOS PHARMA INTERNATIONAL LTD founded?
DANOS PHARMA INTERNATIONAL LTD was officially incorporated on 20 May 2026 and is registered under company number 17233124. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is DANOS PHARMA INTERNATIONAL LTD?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of DANOS PHARMA INTERNATIONAL LTD?
DANOS PHARMA INTERNATIONAL LTD's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does DANOS PHARMA INTERNATIONAL LTD do?
DANOS PHARMA INTERNATIONAL LTD operates in the following sectors: 21200 - Manufacture of pharmaceutical preparations, 46460 - Wholesale of pharmaceutical goods, 47730 - Dispensing chemist in specialised stores, 47749 - Retail sale of medical and orthopaedic goods in specialised stores (not incl. hearing aids) n.e.c.. These SIC codes provide insight into the company's business activities and industry focus.
What is DANOS PHARMA INTERNATIONAL LTD's registered address?
The registered office address of DANOS PHARMA INTERNATIONAL LTD is 27 Old Gloucester Street, London, United Kingdom, WC1N 3AX. This is the official address filed with Companies House for legal and statutory correspondence.
Is DANOS PHARMA INTERNATIONAL LTD financially stable?
Financial accounts for DANOS PHARMA INTERNATIONAL LTD are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.